All In Biotech

NDA 020033 · Validus Pharms

Lotensin Hct

Benazepril Hydrochloride, Hydrochlorothiazide · Oral · Thiazide Diuretic

Last checked: Nov 19, 2026Latest source record: Aug 20, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1992

May 19, 1992

Approved uses

1

Original approval plus efficacy supplements

Registered trials

53

7 Phase 3, 1 recruiting

FAERS reports

447

265 serious, 27 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: FETAL TOXICITY When pregnancy is detected, discontinue Benazepril HCl and Hydrochlorothiazide as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus (see WARNINGS: Fetal Toxicity ) .

What it is approved for

From the label in effect Feb 24, 2026.

INDICATIONS AND USAGE Benazepril HCl and Hydrochlorothiazide is indicated for the treatment of hypertension. This fixed combination drug is not indicated for the initial therapy of hypertension (see DOSAGE AND ADMINISTRATION ) .

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 19, 1992 Original approval · Type 4 - New Combination
4 products under this application
  • LOTENSIN HCT · BENAZEPRIL HYDROCHLORIDE 20MG; HYDROCHLOROTHIAZIDE 25MG · TABLET, ORAL · Prescription · TE AB
  • LOTENSIN HCT · BENAZEPRIL HYDROCHLORIDE 5MG; HYDROCHLOROTHIAZIDE 6.25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued
  • LOTENSIN HCT · BENAZEPRIL HYDROCHLORIDE 20MG; HYDROCHLOROTHIAZIDE 12.5MG · TABLET, ORAL · Prescription · TE AB
  • LOTENSIN HCT · BENAZEPRIL HYDROCHLORIDE 10MG; HYDROCHLOROTHIAZIDE 12.5MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Benazepril" as an intervention, any sponsor and status, largest first.

All 53 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dizziness30
  • diarrhoea24
  • nausea23
  • headache21
  • hypertension21
  • pain19
  • fatigue18
  • blood glucose increased17
  • dyspnoea17
  • pain in extremity16
  • vomiting16
  • arthralgia15

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200410
200519
200615
200711
200819
200921
201019
201118
201224
201316
201436
201525
201635
201724
201839
201932
202022
202113
20224
202310
202410
202512
202613

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Lotensin HCT (Benazepril/Hydrochlorothiazide)

2024 spending

$10K

Beneficiaries

n/a

38 claims

Per beneficiary

n/a

$2.45 per unit

View as table
YearSpending
2020$11,642
2021$10,561
2022$8,474
2023$9,783
2024$10,378

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 252 on PubMed

Sponsor: Validus Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.